Bio-Imaging Technologies Announces First Quarter 2007 Financial Results.

NEWTOWN, Pa. -- Bio-Imaging Technologies, Inc. ("Bio-Imaging") (NASDAQ: BITI) today announced its financial results for the quarter ended March 31, 2007.

Financial highlights for the first quarter 2007 include:

* Service revenues increased 20.9% to $8.8 million for first quarter 2007 as compared to $7.2 million for first quarter 2006.

* Operating income for first quarter 2007 was $502,000 compared to operating loss of $194,000 for first quarter 2006.

* Net income for first quarter 2007 was $395,000, or $0.03 per fully diluted share, versus a net loss of $56,000, or $0.01 per fully diluted share, for first quarter 2006.

* Backlog increased 26.2% to $77.6 million, as of March 31, 2007, as compared to $61.5 million as of March 31, 2006.

Mark L. Weinstein, President and Chief Executive Officer of Bio-Imaging, said, "We continue to experience strong year-over-year operating results both in terms of service revenue and operating income. First quarter service revenue of $8.8 million represented a 20.9% year-over-year increase and fully diluted earnings per share of $0.03 starts us off with a profitable quarter versus a loss of $0.01 per fully diluted share during the first quarter of 2006. Based on the strength of our backlog and the positive trends in service revenue and operating income, we are reiterating our full year 2007 guidance of service revenue in the range of $36-$38 million and earnings per share of $0.12 to $0.16."

First quarter 2007 results include CapMed revenue of $134,000 and operating expenses of $514,000. Mr. Weinstein remarked, "Our hybrid model of providing our personal health record product in three form factors; a USB Healthkey, a desktop application and an online portal model, is attracting a great deal of attention in the marketplace. We believe that combining our multiple form factors with a strong interoperability component is positioning us as a strong potential partner for large employers, payors and hospitals. We are currently working on pilot projects to test various scenarios in search of the best sustainable revenue model. Once the results of these pilot projects are analyzed, we believe there will be larger follow-on projects for CapMed."

Mr. Weinstein added, "First quarter results include two months of the acquisition of Theralys SA which was completed in February 2007. Theralys strengthens our capabilities in the areas of central nervous system disorders ("CNS") and Neurovascular diseases, including stroke, secondary prevention drugs, multiple sclerosis and dementia, including Alzheimer's disease (AD). We are encouraged by the favorable response we have received from our initial marketing of these capabilities to our existing pharmaceutical and biotech clients."

Mr. Weinstein concluded, "We are pleased that we are continuing on a profitable trend and are looking forward to strengthening our operating results as 2007 progresses."

Management of Bio-Imaging Technologies, Inc. will host a conference call today at 11:00 A.M. EDT to discuss the company's financial results and achievements. Those who wish to participate in the conference call may telephone [phone] from the US or [phone] for international callers, passcode #8728298 approximately 15 minutes before the call. There will be a simultaneous webcast under "Investor Relations" at www.bioimaging.com. A digital replay will be available by telephone for two weeks and may be accessed by dialing [phone], from the US, or [phone], for international callers, passcode #8728298. The replay will also be available for two weeks under "Investor Relations" at www.bioimaging.com.

Bio-Imaging Technologies, Inc. is a healthcare contract service organization providing services that support the product development process of the pharmaceutical, biotechnology and medical device industries. The Company has specialized in assisting its clients in the design and management of the medical-imaging component of clinical trials since 1990. Bio-Imaging serves its clients on a global basis through its US Core Lab in Newtown, PA, its European Core Lab in Leiden, The Netherlands and its recent acquisition of Theralys SA in Lyon, France. Through its CapMed division, Bio-Imaging provides the Personal HealthKey[TM] technology and the Personal Health Record (PHR) software allowing patients to better monitor and manage their health care information. Copies of Bio-Imaging Technologies' press releases and other information may be obtained through Bio-Imaging's web site at www.bioimaging.com.

Certain matters discussed in this press release are "forward-looking statements" intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company's statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates made by management with respect to the Company's financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company's control. The factors discussed herein and expressed from time to time in the Company's filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company's filings, especially risk factors contained in the Form 10-K and the recent form 10-Q.

[TABLE OMITTED]
[TABLE OMITTED]
[TABLE OMITTED]